Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal Triamcinolone Acetonide for Retinal Diseases
NCT05288192Unknown
- Sponsor
- Benha University
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of triamcinolone acetonide in diabetic macular edema (DME), retinal detachment and Central serous chorioretinopathy (CSCR) (2 arms), sponsored by Benha University. Primary endpoints: Changes in visual acuity at 6 months and Central foveal thickness at 6 months. Status: unknown.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)retinal detachmentCentral serous chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NCT05288192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288192.